Basilea Pharmaceutica AG (0QNA.L)

CHF 40.65

(-1.81%)

EBITDA Summary of Basilea Pharmaceutica AG

  • Basilea Pharmaceutica AG's latest annual EBITDA in 2023 was 29.49 Million CHF , up 16.68% from previous year.
  • Basilea Pharmaceutica AG's latest quarterly EBITDA in 2024 Q2 was 10.15 Million CHF , down 0.0% from previous quarter.
  • Basilea Pharmaceutica AG reported an annual EBITDA of 26.21 Million CHF in 2022, up 436.13% from previous year.
  • Basilea Pharmaceutica AG reported an annual EBITDA of 6.72 Million CHF in 2021, up 117.29% from previous year.
  • Basilea Pharmaceutica AG reported a quarterly EBITDA of N/A for 2023 FY, up 16.68% from previous quarter.
  • Basilea Pharmaceutica AG reported a quarterly EBITDA of 38.65 Million CHF for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Basilea Pharmaceutica AG (2023 - 2002)

Historical Annual EBITDA of Basilea Pharmaceutica AG (2023 - 2002)

Year EBITDA EBITDA Growth
2023 29.49 Million CHF 16.68%
2022 26.21 Million CHF 436.13%
2021 6.72 Million CHF 117.29%
2020 -2.23 Million CHF -34.74%
2019 -14.12 Million CHF 27.3%
2018 -22.75 Million CHF -74.81%
2017 -7.3 Million CHF 70.61%
2016 -41.67 Million CHF 29.56%
2015 -58.83 Million CHF -49.62%
2014 -38.92 Million CHF -29.34%
2013 -30.57 Million CHF 35.24%
2012 -47.2 Million CHF 13.18%
2011 -54.37 Million CHF -148.67%
2010 111.71 Million CHF 196.1%
2009 -116.24 Million CHF 21.66%
2008 -148.38 Million CHF -19.55%
2007 -133.76 Million CHF -51.02%
2006 -82.18 Million CHF -79.17%
2005 -45.86 Million CHF 35.57%
2004 -71.18 Million CHF -39.22%
2003 -51.13 Million CHF 13.99%
2002 -59.45 Million CHF 0.0%

Peer EBITDA Comparison of Basilea Pharmaceutica AG

Name EBITDA EBITDA Difference
Relief Therapeutics Holding AG -108.2 Million CHF 127.259%
Tecan Group AG 205.57 Million CHF 85.652%
Santhera Pharmaceuticals Holding AG 79.17 Million CHF 62.747%
Bachem Holding AG 163.27 Million CHF 81.935%
Siegfried Holding AG 241.21 Million CHF 87.772%
Molecular Partners AG -59.51 Million CHF 149.559%